Bioengineered Internal Anal Sphincter

Phase 1Biologic

Bioengineered Internal Anal Sphincter is one of 6 biologic programs targeting Fecal Incontinence. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fecal IncontinenceActive, not recruiting

Fecal IncontinencePhase 1

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Fecal Incontinence

#DrugCompanyPhaseTrials

Flagyl

DDePuy Orthopaedics

Approved

—2

Neo-Synephrine

EExela Pharma Sciences, LLC.

Iltamiocel

2 4

Botulinum Toxin a

GSK

Phase 1

1 5

Bioengineered Internal Anal Sphincter

CCellf Bio LLC

Phase 1

1 6

Polyethylene Glycols

JJinnah Postgraduate Medical Centre

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Fecal Incontinence

NCT05616208

Clinical

Trials by Indication[1]

Fecal Incontinence1 trial

Implantation of BioSphincter TM for Treatment of Severe Passive Fecal Incontinence

Active, not recruiting·CCellf Bio LLC·Phase 1·NCT05616208·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bioengineered Internal Anal Sphincter. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bioengineered Internal Anal Sphincter compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bioengineered Internal Anal Sphincter. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cellf Bio LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCellf Bio LLC

Bioengineered Internal Anal Sphincter

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Fecal Incontinence1 trial

References

Drug Info

Quick Facts

Related News